CYCC Logo

Cyclacel Pharmaceuticals, Inc. (CYCC) 

NASDAQ
Market Cap
$890,783.00
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
294 of 776
Rank in Industry
169 of 433

Largest Insider Buys in Sector

CYCC Stock Price History Chart

CYCC Stock Performance

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced …

Insider Activity of Cyclacel Pharmaceuticals, Inc.

Over the last 12 months, insiders at Cyclacel Pharmaceuticals, Inc. have bought $26,374 and sold $0 worth of Cyclacel Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Cyclacel Pharmaceuticals, Inc. have bought $26,374 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Rombotis Spiro George (President and CEO) — $20,122. McBarron Paul (See Remarks) — $6,252.

The last purchase of 6,070 shares for transaction amount of $20,122 was made by Rombotis Spiro George (President and CEO) on 2023‑12‑21.

List of Insider Buy and Sell Transactions, Cyclacel Pharmaceuticals, Inc.

2023-12-21PurchasePresident and CEO
6,070
0.6595%
$3.31$20,122-43.89%
2023-12-21PurchaseSee Remarks
1,886
0.2049%
$3.31$6,252-43.89%
2017-02-23Purchase10 percent owner
134,200
3.3648%
$4.34$582,079-53.33%
2014-11-20Purchasedirector
3,100
0.0137%
$3.00$9,300-75.93%
2013-05-21PurchasePresident and CEO
200,000
1.4075%
$3.00$600,000+16.94%
2013-05-21PurchaseSee Remarks
12,948
0.092%
$3.03$39,213+16.94%
2013-05-21Purchasedirector
33,333
0.2346%
$3.00$99,999+16.94%
2011-12-23PurchasePresident and CEO
15,902
0.0288%
$0.49$7,871+16.00%
2011-09-23Sale10 percent owner
650,000
1.2397%
$0.51$332,930+11.43%
2011-09-23PurchasePresident and CEO
24,100
0.0453%
$0.51$12,171+11.43%
2011-09-23PurchaseSee Remarks
12,000
0.0223%
$0.50$6,000+11.43%
2011-09-22Sale10 percent owner
500,000
1.0235%
$0.60$302,350+0.65%
2011-09-22PurchasePresident and CEO
5,000
0.01%
$0.59$2,965+0.65%
2011-09-13PurchasePresident and CEO
12,400
$0.75$9,343-23.61%
2011-08-22PurchasePresident and CEO
9,232
0.0171%
$0.73$6,721-21.92%
2011-05-13Sale10 percent owner
150,000
0.3324%
$1.75$263,200-61.18%
2010-11-30Sale10 percent owner
142,000
0.3167%
$1.90$269,871-29.51%
2010-11-26Sale10 percent owner
58,000
0.1253%
$1.90$110,310-31.75%
2010-10-08Sale10 percent owner
183,982
0.3957%
$1.67$307,728-17.07%
2010-05-04SaleVP, Marketing & Sales
10,000
0.0049%
$0.44$4,400-36.59%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.